Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05556226 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT05556226 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 40 participants.
The verdict
NCT05556226, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will assess how safe ABBV-154 is and how ABBV-154 moves through the body of adult healthy participants. Adverse Events will be assessed. ABBV-154 is an investigational drug being developed for potential treatment of immune-mediated inflammatory diseases. Participants are randomly assigned to one of the 2 treatment groups. Approximately 40 adult healthy volunteers will be enrolled in 2 sites in the United States. All participants will receive ABBV-154 as subcutaneous injections with one of the 2 different formulations. There may be higher burden for participants in this trial. Participants will be confined for 9 days. Adverse Events and blood tests will be performed.
Interventions
- DRUG ABBV-154 Dose Formulation A
- DRUG ABBV-154 Dose Formulation B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-10-18 |
| Est. Completion | 2023-02-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05556226
The ClinicalTrials.gov registry entry for NCT05556226 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABBV-154 Dose Formulation A is the first listed.
NCT05556226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05556226 about?
NCT05556226 is a clinical study titled "Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants". This study will assess how safe ABBV-154 is and how ABBV-154 moves through the body of adult healthy participants. Adverse Events will be assessed. ABBV-154 is an investigational drug being developed for potential treatment of immune-mediated inflammatory diseases. Participants are randomly assigne...
What is the current status of trial NCT05556226?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2022-10-18. Estimated completion is 2023-02-17.
What interventions are being tested in trial NCT05556226?
The interventions under investigation include: ABBV-154 Dose Formulation A (DRUG), ABBV-154 Dose Formulation B (DRUG).
Who is sponsoring clinical trial NCT05556226?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.